Larimar Therapeutics Inc. (LRMR), which is developing a drug for a rare inherited condition, has clinical data readouts expected later this year that investors should watch closely.
The company's lead drug candidate is Nomlabofusp, being developed as a potential disease-modifying therapy for Friedreich's ataxia.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com